MAY 10, 2017 10:30 AM PDT

Delivering on the promise of Personalized Molecular Medicine

C.E. CREDITS: CEU | P.A.C.E. CE | Florida CE
Speakers
  • Department Chair, Department of Systems Biology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center
    Biography

      Gordon B. Mills, MD, PhD, was recruited to The University of Texas M. D. Anderson Cancer Center in 1994, where he holds the rank of Professor with joint appointments in Systems Biology, Breast Medical Oncology and Immunology; serves as chairman of the Department of Systems Biology; head of the section of Molecular Therapeutics and holds the Wiess Distinguished University Chair in Cancer Medicine. Dr. Mills is co-Director of the Kleberg Center for Molecular Markers and Director for the Gita and Ali Saberioon Molecular Markers building. This Center is responsible for developing personalized molecular medicine at MDACC. Dr. Mills has published extensively on the molecular analysis of cancer and currently serves as principal investigator or project investigator on many national peer review grants including NIH/NCI SPOREs and PPGs, Department of Defense, and Komen Foundation grants, and is a collaborator on multiple other national grants. Dr. Mills also holds more than 20 patents related to novel technologies and molecular markers and has co-founded an early diagnostics company. He currently sits on the scientific advisory boards of multiple companies and venture capital groups. Based on his expertise in technology development, he is the head of the M. D. Anderson Cancer Center Technology Review Committee.
       
       

    Abstract:

    The realization of the promise of personalized molecular medicine requires efficient development and implementation of novel targeted therapeutics linked to molecular markers able to identify patients most likely to benefit. An efficient integration of DNA, RNA and protein information content will be needed to identify patients likely to respond to particular therapies. The plethora of aberrations present in each tumor, the need to distinguish drivers from passengers, and the combinatorial effects of aberrations on critical cellular functions represent key challenges. The overall likelihood of response to therapy represents the interaction between predictors of sensitivity and predictors of resistance. Resistance can be pre-existing, adaptive, or acquired. Resistance can also occur through heterogeneity of molecular changes within the tumor and metastases. Adaptive resistance, which is the consequence of activation of homeostatic loops and phylogenetically conserved stress responses, provides a potential therapeutic liability that can be leveraged for rational combinatorial therapy. Thus a comprehensive analysis of patient tumors before, during and after treatment should become the standard of practice. Testing these precepts will require the development and implementation of novel trial designs. It is likely that we will need to increase the size of phase I and II trials to allow the identification and validation of molecular markers at the same time as the initial evaluation the toxicity and efficacy of targeted therapeutics. This will come with the advantage of much smaller phase III trials of patients selected for the likelihood to respond accelerating the approval of effective targeted therapeutics. 


    Show Resources
    You May Also Like
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    APR 25, 2018 07:00 AM PDT
    C.E. CREDITS
    APR 25, 2018 07:00 AM PDT
    DATE: April 25, 2018TIME: 1500 CET, 10:00 a.m. EST, 7:00 a.m. PST Hematology and coagulation laboratories perform a wide range of routine and specialized tests, allowing clinicians to...
    Loading Comments...